Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Gilead Sciences Inc (GILD)

Gilead Sciences Inc (GILD)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 85,647,824
  • Shares Outstanding, K 1,254,178
  • Annual Sales, $ 24,689 M
  • Annual Income, $ 123,000 K
  • 60-Month Beta 0.38
  • Price/Sales 3.55
  • Price/Cash Flow 8.39
  • Price/Book 4.64
Trade GILD with:

Options Overview

Details
  • Implied Volatility 17.57%
  • Historical Volatility 15.04%
  • IV Percentile 0%
  • IV Rank 0.00%
  • IV High 40.33% on 01/04/21
  • IV Low 17.57% on 08/05/21
  • Put/Call Vol Ratio 0.51
  • Today's Volume 10,161
  • Volume Avg (30-Day) 15,256
  • Put/Call OI Ratio 0.69
  • Today's Open Interest 618,001
  • Open Int (30-Day) 602,660

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate 1.64
  • Number of Estimates 8
  • High Estimate 1.79
  • Low Estimate 1.47
  • Prior Year 2.11
  • Growth Rate Est. (year over year) -22.27%

Price Performance

See More
Period Period Low Period High Performance
1-Month
67.37 +2.86%
on 07/15/21
70.40 -1.56%
on 07/29/21
unch (unch)
since 07/02/21
3-Month
65.12 +6.42%
on 06/01/21
70.40 -1.56%
on 07/29/21
+2.79 (+4.19%)
since 05/05/21
52-Week
56.56 +22.52%
on 12/31/20
70.40 -1.56%
on 07/29/21
+0.30 (+0.43%)
since 08/05/20

Most Recent Stories

More News
FATE Reports Wider-Than-Expected Q2 Loss, Beats on Revenues

FATE reports a wider loss on increased R&D expenses in the second quarter.

BMY : 68.42 (-0.10%)
JNJ : 173.69 (+0.19%)
GILD : 69.30 (+0.09%)
FATE : 95.54 (+11.44%)
Kite and Appia Bio Announce Collaboration to Research and Develop Allogeneic Cell Therapies for Cancer

Kite, a Gilead Company (Nasdaq: GILD), and Appia Bio, Inc., an early stage biotechnology company developing engineered allogeneic cell therapies from hematopoietic stem cells (HSCs) for cancer patients,...

CELU : 8.00 (-7.73%)
GILD : 69.30 (+0.09%)
BioNTech Completes Acquisition of Kite's Neoantigen TCR Cell Therapy R&D Platform and Manufacturing Facility in Gaithersburg, Maryland

BioNTech SE (Nasdaq: BNTX, "BioNTech") and Kite, a Gilead Company (Nasdaq: GILD, "Kite") today announced the closing of the acquisition of the solid tumor neoantigen T cell receptor (TCR) R&D platform...

GILD : 69.30 (+0.09%)
BNTX : 404.92 (-2.30%)
International AIDS Society Leaders on the Future of HIV Prevention and Treatment

--News Direct--

GILD : 69.30 (+0.09%)
Gilead Sciences Endows Its Foundation With More Than $200 Million to Support Health Justice, Community Giving and Employee Match Program

Gilead Sciences, Inc. (Nasdaq: GILD) today announced a more than $200 million endowment to the Gilead Foundation to further the company's vision of creating a healthier world for all people. The Gilead...

GILD : 69.30 (+0.09%)
Intercept's (ICPT) Q2 Loss Narrower Than Expected, Sales Beat

Intercept (ICPT) posts a narrower loss in the second quarter and sales beat estimates.

NVO : 103.10 (+4.98%)
GILD : 69.30 (+0.09%)
ICPT : 16.87 (+2.12%)
VKTX : 6.15 (+5.13%)
Gilead (GILD) Q2 Earnings Beat Estimates, HIV Sales Decline

Gilead (GILD) beats on sales and earnings in the second quarter. While the HIV business lags due to generic competition, Veklury maintains momentum.

GSK : 40.92 (+1.04%)
MRK : 75.59 (+0.15%)
GILD : 69.30 (+0.09%)
RGEN : 254.67 (+0.82%)
Ligand (LGND) Q2 Earnings & Sales Beat, 2021 Guidance Cut

Ligand (LGND) reports encouraging second-quarter 2021 numbers by beating estimates on both counts.

MRK : 75.59 (+0.15%)
AMGN : 233.99 (+2.49%)
GILD : 69.30 (+0.09%)
LGND : 108.97 (-0.08%)
Stocks Fall as a -6% Plunge in Amazon Stokes Growth Concerns for Big Tech Companies

The S&P 500 Index ($SPX ) this morning is down -0.32%, the Dow Jones Industrials Index ($DOWI ) is down -0.14%, and the Nasdaq 100 Index ($IUXX ) is down -0.58%. U.S stock indexes this morning are moderately...

$SPX : 4,429.10 (+0.60%)
$DOWI : 35,064.25 (+0.78%)
$IUXX : 15,181.64 (+0.65%)
ZNU21 : 134-125 (unch)
DXY00 : 92.324 (+0.09%)
^EURUSD : 1.18261 (-0.05%)
^USDJPY : 109.843 (+0.06%)
GCZ21 : 1,804.2 (-0.26%)
SIU21 : 25.150 (-0.56%)
SWKS : 185.79 (-0.54%)
AMZN : 3,375.99 (+0.63%)
EBAY : 67.28 (-1.06%)
ETSY : 182.41 (-9.74%)
W : 276.16 (+10.00%)
GILD : 69.30 (+0.09%)
PG : 142.50 (+0.05%)
$VIX : 17.28 (-3.84%)
Pre-Market Stock Preview: U.S. Stock Index Futures Tumbles as Amazon.com Tanks on Disappointing Earnings Results

Morning Markets Sep S&P 500 futures this morning are down -0.69%, as a -6% plunge in Amazon.com in pre-market trading stokes concern about slowing growth at mega-cap technology companies. S&P futures...

AMZN : 3,375.99 (+0.63%)
PINS : 60.33 (+0.33%)
TXRH : 91.11 (+2.35%)
FSLR : 91.62 (-0.64%)
GILD : 69.30 (+0.09%)
TRVG : 2.99 (+3.10%)
WY : 34.48 (+1.29%)
CVX : 101.23 (+0.93%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The Company strive to transform and simplify care for people with life-threatening illnesses around the world. Gilead's portfolio of products...

See More

Key Turning Points

3rd Resistance Point 70.40
2nd Resistance Point 69.87
1st Resistance Point 69.58
Last Price 69.30
1st Support Level 68.76
2nd Support Level 68.23
3rd Support Level 67.94

See More

52-Week High 70.40
Last Price 69.30
Fibonacci 61.8% 65.11
Fibonacci 50% 63.48
Fibonacci 38.2% 61.85
52-Week Low 56.56

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar